Can a patient with a history of Coronary Artery Bypass Graft (CABG) take Viagra (sildenafil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Viagra Use After CABG: Safety Considerations and Recommendations

Patients with a history of CABG can safely take Viagra (sildenafil) as long as they are not using nitrate medications, which is an absolute contraindication due to risk of severe hypotension.

Safety Assessment Algorithm

  1. Nitrate Medication Check

    • Absolute contraindication: Patients taking any form of nitrates (nitroglycerin, isosorbide mononitrate/dinitrate) CANNOT take sildenafil 1
    • The combination can cause severe, potentially fatal hypotension
    • If on long-acting nitrates, they must be discontinued before considering sildenafil
  2. Cardiovascular Stability Assessment

    • Ensure patient is:
      • Hemodynamically stable
      • Free from unstable angina
      • At least 6-8 weeks post-CABG surgery (when sternotomy is well-healed) 1
      • Not within 6 months of acute MI or stroke 2
  3. Exercise Capacity Evaluation

    • Sexual activity requires 3-5 METs (metabolic equivalents) of exertion 1, 3
    • Patient should be able to:
      • Climb two flights of stairs or
      • Walk briskly for 6 minutes without symptoms
      • Complete cardiac rehabilitation if possible 1

Clinical Considerations

Benefits

  • Improved quality of life and psychological well-being
  • Sexual dysfunction is common after CABG and addressing it is important for recovery 1
  • Sildenafil has been shown to be safe in patients with stable coronary artery disease who are not on nitrates 3, 2

Hemodynamic Effects

  • Sildenafil causes modest blood pressure reduction (approximately 8/6 mmHg) 4
  • No significant changes in heart rate or cardiac output at therapeutic doses 4
  • May actually improve coronary flow reserve in some patients with coronary artery disease 5

Risk Stratification

  • Low risk: Asymptomatic, completed cardiac rehabilitation, good functional capacity
  • Intermediate risk: Controlled symptoms, moderate functional capacity
  • High risk (avoid sildenafil): Unstable angina, uncontrolled hypertension, severe heart failure, recent MI/stroke

Important Precautions

  • Start with lowest effective dose (25mg) in post-CABG patients
  • Educate patient about potential side effects: headache, flushing, dyspepsia
  • Emergency protocol: If chest pain occurs during sexual activity:
    • Stop activity immediately
    • If taking sildenafil, DO NOT take nitroglycerin for at least 24 hours (48 hours for tadalafil) 1
    • Call emergency services if chest pain persists >15 minutes 1

Common Pitfalls to Avoid

  1. Nitrate interaction: Never prescribe sildenafil to patients using any form of nitrates
  2. Inadequate risk assessment: Failing to assess exercise capacity before recommending sildenafil
  3. Ignoring timing: Prescribing too soon after CABG (before adequate healing)
  4. Medication reconciliation errors: Not checking for drug interactions with other post-CABG medications
  5. Inadequate patient education: Not informing about emergency protocols if chest pain occurs

Sildenafil can be a safe and effective treatment for erectile dysfunction in most post-CABG patients who are stable, not taking nitrates, and have adequate exercise capacity. The benefits to quality of life often outweigh the small cardiovascular risks in appropriately selected patients.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The clinical safety of viagra.

Annals of the New York Academy of Sciences, 2002

Research

Effects of sildenafil citrate on human hemodynamics.

The American journal of cardiology, 1999

Research

Phosphodiesterase 5 inhibition: effects on the coronary vasculature.

International journal of clinical practice, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.